Product Information
RELPAX 20 MG TABLET is a brand product labeled by Viatris Specialty LLC, priced at $77.3705 per EA under NDC 58151036756. Its NADAC has been published 65 times since Jul 9, 2025.
FDA first approved this application on Dec 26, 2002. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
20 mg/1
Manufacturer
Viatris Specialty LLCNDC
58151036756
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ELETRIPTAN HYDROBROMIDEApproval Type
New Drug (NDA)
FDA Application
NDA021016FDA Approved
12/26/2002
TE Code
AB
On Market Since
5/8/2025
Pharmacological Classes
Price Statistics
The NADAC for RELPAX 20 MG TABLET has been published 65 times since Jul 9, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $77.3705 per EA |
|---|---|
| All-time high | $78.1117 (Jul 15, 2026) |
| All-time low | $77.1903 (May 20, 2026) |
| 52-week high | $78.1117 |
| 52-week low | $77.1903 |
| Median price | $77.5667 |
| Average price | $77.5405 |
| Largest weekly change | +1.2% (Jun 17, 2026) |
| Weeks tracked | 65 |
| Tracking since | Jul 9, 2025 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 98% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Viatris Specialty LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
eletriptan hydrobromide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RELPAX 20 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RELPAX 20 MG TABLET, manufactured by Viatris Specialty LLC, is $77.3705 per EA (NDC 58151036756), effective Sep 30, 2026.
How has the price of RELPAX 20 MG TABLET changed over time?
Over the history we have for it, the NADAC for RELPAX 20 MG TABLET has held within roughly two percent of its current level. It has been tracked across 65 weekly CMS publications since Jul 9, 2025.
What are the highest and lowest recorded NADAC prices for RELPAX 20 MG TABLET?
Since Jul 9, 2025, the NADAC for RELPAX 20 MG TABLET has ranged from a low of $77.1903 (May 20, 2026) to a high of $78.1117 (Jul 15, 2026), with a median of $77.5667 per EA.
Are there cheaper alternatives to RELPAX 20 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ELETRIPTAN HBR 20 MG TABLET, is $1.7293 per EA — about 98% below RELPAX 20 MG TABLET.
Who manufactures RELPAX 20 MG TABLET?
RELPAX 20 MG TABLET (NDC 58151036756) is labeled by Viatris Specialty LLC, and CMS classifies it as a brand product.